Atlas Trials

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Clinical trial NCT03091465 · COMPLETED

Trial details

NCT number
NCT03091465
Sponsor
Spanish Oncology Genito-Urinary Group
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Renal Cell Carcinoma
Start date
2016-12-20
Primary completion
2017-04-17
Enrollment
530

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.